Skip to content

Effect of Pain balm on Headache

A Randomized, Multicentric,Open label,Interventional study to evaluate the Efficacy and Tolerability of four types of AMRUTANJAN PAIN BALM for pain relief in patients with primary type of HEADACHE and BODY PAIN disorders.

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/026013
Enrollment
144
Registered
2020-06-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G448- Other specified headache syndromes

Interventions

Intervention1: New Amrutanjan Pain Balm Extra Power (NAPBEP): Apply pea ball-sized amount (equivalent to 0.25g) of the pain balm in thin layer to the pain area. Intervention2: Amrutanjan Strong Pain

Sponsors

Amrutanjan Health Care Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex aged above 18 years. 2. Patients who are able to understand written and/or verbal instructions and are ready to comply with all study requirements with a willingness to participate and give written informed consent voluntarily. 3. Patients who had been diagnosed with body pain disorders like knee pain, low back pain and primary type of headache disorders like migraine, tension type headache and other primary head ache disorders.

Exclusion criteria

Exclusion criteria: 1. Women of child bearing potential who are either unwilling or unable to use an acceptable method of birth control [such as oral contraceptives, other hormonal contraceptives (implants or injectable products, vaginal products, skin patches), or IUDs, barrier methods] to avoid pregnancy during the study period. 2. Secondary type of headache disorders. 3. Known allergy to compounds of investigational product. 4. Subjects who had a diagnosis of basilar or hemiplegic migraine. 5. Patients suffering from medical or psychiatric conditions that would increase the risk of adverse events or interfere with study assessments. 6. Participation in an investigational drug trial in the 30 days prior to the screening visit. 7. Immuno-compromised (history) individuals like known HIV positive patients or patients who are on treatment with steroids or immunomodulators. 8. Patients of vulnerable group (children, lactating mother, elderly >80 years, handicapped, seriously ill, mentally challenged). 9. History of drug or alcohol abuse during the last 6 months.

Design outcomes

Primary

MeasureTime frame
ï?? To assess the onset of pain reduction after treatment at 30 seconds, 1 min, 2 min, 5 min, 10 min, 30 min and 60 min.(using visual analog scale) ï?? To assess the duration of action (i.e need for second application) of the test product for pain relief.(time frame : 0-24 hours) Timepoint: 30 seconds, 1 min, 2 min, 5 min, 10 min, 30 min and 60 min

Secondary

MeasureTime frame
ï?? To monitor other complications like skin rashes, redness, photophobia, and phonophobia.Timepoint: 0-24 hours

Countries

India

Contacts

Public ContactDr Ramesh kannan

KI3, CRO

srkguruvarshan@gmail.com7708925866

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026